GSK as reported
GSK plc reported £32.7B of revenue over the trailing twelve months, +32% on the year before. 10 reported series are charted on this page, each one as filed.
£32.7B
Revenue, trailing twelve months · to FY2025 · +32% against the twelve months before
- Net Income
- £5.72B
Net Income · +30% year on year · trailing twelve months to FY2025
- Free Cash Flow
- £6.39B
Free Cash Flow · −8.7% year on year · trailing twelve months to FY2025
- Op Margin
- 24%
Op Margin · trailing twelve months to FY2025
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | £32.7B | +32% | FY2025 |
| Net Income | £5.72B | +30% | FY2025 |
| EPS | £1.39 | +28% | FY2025 |
| Gross Margin | 72% | n/a | FY2025 |
| Op Margin | 24% | n/a | FY2025 |
| Net Margin | 17% | n/a | FY2025 |
| ROE | 35% | n/a | FY2025 |
| ROA | 9.4% | n/a | FY2025 |
| ROIC | 20% | n/a | FY2025 |
| Free Cash Flow | £6.39B | −8.7% | FY2025 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
GSK plc (GSK) - Revenue & ProfitRevenue & ProfitGSK plc (GSK)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Drug Manufacturers - General
Ranks #8 of 16 by Smart Score